Objective: Large inter-individual variability in the pharmacokinetics of rilpivirine and cabotegravir has been reported in the first weeks after starting long-acting injectable (LAI) therapy. Here, we assessed the distribution of rilpivirine and cabotegravir trough concentrations in people with HIV (PWH) on long-term LAI treatment. Methods: Adult PWH treated with LAI for at least 32 weeks with an assessment of drug plasma trough concentrations were considered. The proportion of rilpivirine and cabotegravir plasma trough concentrations below four-times the protein-adjusted concentrations required for 90% inhibition of viral replication (4xPA-IC90) was estimated. Results: Sixty-seven PWH were identified. LAI treatment duration was 216 +/- 80 weeks (range 32-320 weeks). Cabotegravir concentrations were associated with lower inter-individual variability compared with rilpivirine (45% versus 84%; P < 0.05). No differences were found in rilpivirine (160 +/- 118 versus 189 +/- 81 ng/mL; P = 0.430) and cabotegravir (1758 +/- 807 versus 1969 +/- 802 ng/mL; P = 0.416) trough concentrations in males (n = 55) versus females (n = 12). A non-significant trend for lower cabotegravir concentrations was found in PWH with a body mass index >30 kg/m(2) (n = 9) versus non-obese participants (1916 +/- 905 versus 1606 +/- 576 ng/mL; P = 0.131). Three out of the 67 PWH had at least one drug concentration <4xPA-IC90: 100% of PWH had undetectable HIV viral load. Conclusions: At steady state, optimal systemic exposure of cabotegravir and rilpivirine was found in most PWH; cabotegravir trough concentrations were associated with lower inter-individual variability compared with rilpivirine. The study was not powered to assess the contribution of sex and/or body weight on LAI exposure due to the small number of females and obese PWH included.

Rilpivirine and cabotegravir trough concentrations in people with HIV on long-term treatment with long-acting injectable antiretrovirals / M. Vittoria Cossu, D. Cattaneo, D. Moschese, A. Giacomelli, S. Soloperto, A. D’Avolio, S. Antinori, A. Gori, G. Rizzardini, C. Gervasoni. - In: JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. - ISSN 0305-7453. - (2024), pp. dkae080.1-dkae080.7. [Epub ahead of print] [10.1093/jac/dkae080]

Rilpivirine and cabotegravir trough concentrations in people with HIV on long-term treatment with long-acting injectable antiretrovirals

A. Giacomelli;S. Antinori;A. Gori;
2024

Abstract

Objective: Large inter-individual variability in the pharmacokinetics of rilpivirine and cabotegravir has been reported in the first weeks after starting long-acting injectable (LAI) therapy. Here, we assessed the distribution of rilpivirine and cabotegravir trough concentrations in people with HIV (PWH) on long-term LAI treatment. Methods: Adult PWH treated with LAI for at least 32 weeks with an assessment of drug plasma trough concentrations were considered. The proportion of rilpivirine and cabotegravir plasma trough concentrations below four-times the protein-adjusted concentrations required for 90% inhibition of viral replication (4xPA-IC90) was estimated. Results: Sixty-seven PWH were identified. LAI treatment duration was 216 +/- 80 weeks (range 32-320 weeks). Cabotegravir concentrations were associated with lower inter-individual variability compared with rilpivirine (45% versus 84%; P < 0.05). No differences were found in rilpivirine (160 +/- 118 versus 189 +/- 81 ng/mL; P = 0.430) and cabotegravir (1758 +/- 807 versus 1969 +/- 802 ng/mL; P = 0.416) trough concentrations in males (n = 55) versus females (n = 12). A non-significant trend for lower cabotegravir concentrations was found in PWH with a body mass index >30 kg/m(2) (n = 9) versus non-obese participants (1916 +/- 905 versus 1606 +/- 576 ng/mL; P = 0.131). Three out of the 67 PWH had at least one drug concentration <4xPA-IC90: 100% of PWH had undetectable HIV viral load. Conclusions: At steady state, optimal systemic exposure of cabotegravir and rilpivirine was found in most PWH; cabotegravir trough concentrations were associated with lower inter-individual variability compared with rilpivirine. The study was not powered to assess the contribution of sex and/or body weight on LAI exposure due to the small number of females and obese PWH included.
Settore MED/17 - Malattie Infettive
2024
26-mar-2024
Article (author)
File in questo prodotto:
File Dimensione Formato  
Cossu JAC.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 401.93 kB
Formato Adobe PDF
401.93 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/1043469
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 0
social impact